- Home
- FVCB vs DRUG Comparison
FVCB vs DRUG Comparison
Compare FVCB & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FVCB
- DRUG
- Stock Information
- Founded
- FVCB 2007
- DRUG 2019
- Country
- FVCB United States
- DRUG United States
- Employees
- FVCB N/A
- DRUG N/A
- Industry
- FVCB Major Banks
- DRUG Pharmaceuticals and Biotechnology
- Sector
- FVCB Finance
- DRUG Health Care
- Exchange
- FVCB Nasdaq
- DRUG Nasdaq
- Market Cap
- FVCB 248.5M
- DRUG 260.6M
- IPO Year
- FVCB N/A
- DRUG N/A
- Fundamental
- Price
- FVCB $11.81
- DRUG $36.78
- Analyst Decision
- FVCB
- DRUG Strong Buy
- Analyst Count
- FVCB 0
- DRUG 3
- Target Price
- FVCB N/A
- DRUG $80.00
- AVG Volume (30 Days)
- FVCB 24.5K
- DRUG 79.3K
- Earning Date
- FVCB 01-28-2025
- DRUG 12-31-2024
- Dividend Yield
- FVCB N/A
- DRUG N/A
- EPS Growth
- FVCB N/A
- DRUG N/A
- EPS
- FVCB 0.27
- DRUG N/A
- Revenue
- FVCB $45,550,000.00
- DRUG N/A
- Revenue This Year
- FVCB N/A
- DRUG N/A
- Revenue Next Year
- FVCB $14.51
- DRUG N/A
- P/E Ratio
- FVCB $43.28
- DRUG N/A
- Revenue Growth
- FVCB N/A
- DRUG N/A
- 52 Week Low
- FVCB $9.78
- DRUG $0.93
- 52 Week High
- FVCB $14.50
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- FVCB 43.16
- DRUG 46.15
- Support Level
- FVCB $11.27
- DRUG $35.02
- Resistance Level
- FVCB $12.40
- DRUG $38.00
- Average True Range (ATR)
- FVCB 0.62
- DRUG 3.09
- MACD
- FVCB -0.01
- DRUG -0.37
- Stochastic Oscillator
- FVCB 24.38
- DRUG 30.44
About FVCB FVCBankcorp Inc.
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, FVCbank which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.